Free Trial
→ 9/9 on TSLA from June to January (From Wealthpin Pro) (Ad)

Aclarion Q3 2023 Earnings Report

Aclarion logo
$5.11 -0.16 (-3.04%)
As of 02/21/2025 04:00 PM Eastern
Earnings HistoryForecast

Aclarion EPS Results

Actual EPS
-$643.20
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Aclarion Revenue Results

Actual Revenue
$0.02 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Aclarion Announcement Details

Quarter
Q3 2023
Date
11/14/2023
Time
N/A

Conference Call Resources

Aclarion Earnings Headlines

Aclarion, Inc. (ACON) to Showcase NOCISCAN’s Impact on Spine Surgery at 2025 Spine Summit
February 20 at 4:37 PM | msn.com
Aclarion to Showcase Groundbreaking NOCISCAN Technology at the 2025 Spine Summit
February 20 at 6:00 AM | globenewswire.com
The FED is losing the war on inflation
It's no longer just a “guesstimate” – Inflation is indeed getting worse. And although we want to believe the Fed has a good grip on it, they don't. Right now, the suits over there are caught between a rock and a hard place. Either they watch as inflation grows, or they tear it down and send us into a full-blown recession. The kicker here is that neither of these are good for you. Whichever pill we end up with, prices will still climb higher as the value of the dollar sinks lower. The only real way out for the regular person is to increase your earning power. By increasing your income to match prices as they flare up… You’ll stay ahead of the impending doom we're running face-first into. And if you're looking for a strategy to help increase your income in 2025… I've got just the thing for you! You see, last year, I was able to grow a $10k model account to a little over $63k with 100 trade alerts But I changed my trading rules and more than doubled my results on those 100 published trades. I'm now calling them Warped Options…
February 22, 2025 | WealthPress (Ad)
Aclarion Wins Patent, Shares Eke Up
February 11, 2025 | baystreet.ca
Aclarion receives U.S. patent on expanded applications of MRS data processing
February 11, 2025 | markets.businessinsider.com
Aclarion Receives US Patent to Protect Expanded Applications of Magnetic Resonance Spectroscopy (MRS) Data Processing to Identify Pain and Infection Biomarkers Throughout the Body
February 11, 2025 | globenewswire.com
See More Aclarion Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Aclarion? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Aclarion and other key companies, straight to your email.

About Aclarion

Aclarion (NASDAQ:ACON), a healthcare technology company, leverages for Magnetic Resonance Spectroscopy (MRS) in the United States. It develops NOCISCAN Post-Processor suite of software applications comprising NOCICALC that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra and performs various degenerative pain biomarker; and NOCIGRAM, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

View Aclarion Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles